FENC - フェネック・ファ―マシュ―ティカルズ (Fennec Pharmaceuticals Inc.) フェネック・ファ―マシュ―ティカルズ

 FENCのチャート


 FENCの企業情報

symbol FENC
会社名 Fennec Pharmaceuticals Inc (フェネック・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フェネック・ファーマシューティカルス(Fennec Pharmaceuticals Inc.)( 旧名:Adherex Technologies Inc.)はガンの治療法に焦点を当てる生物薬剤会社である。同社のリード製品は、臨床開発段階にある、チオ硫酸ナトリウム(STS)とエニルウラシルを含む。STSは、子供のシスプラチン難聴或いは耳毒性の予防のための第Ⅲ相臨床試験にある化学還元剤とする水溶性チオール化合物である。エニルウラシルは、ジヒドロピリミジン・デヒドロゲナーゼ(DPD)の不可逆阻害剤であり、主に体内で5-FUの急速な分解に関与する酵素である。   フェネック・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、主にがん治療用の医薬品の開発に従事する。チオ硫酸ナトリウムは抗がん剤のシスプラチン誘発性難聴の予防に使用、エニルウラシルは経口薬で転移性乳がんの治療に使用される。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。   Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.
本社所在地 P.O. Box 13628 68 T.W. Alexander Drive Research Triangle Park NC 27709 USA
代表者氏名 Khalid Islam ハリドイスラム
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-636-4530
設立年月日 36039
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 3人
url www.adherex.com
nasdaq_url https://www.nasdaq.com/symbol/fenc
adr_tso
EBITDA EBITDA(百万ドル) -9.15700
終値(lastsale) 7.89
時価総額(marketcap) 148284391.74
時価総額 時価総額(百万ドル) 147.15680
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 121.51680
当期純利益 当期純利益(百万ドル) -8.79700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fennec Pharmaceuticals Inc revenues was not reported. Net loss increased 73% to $4.2M. Higher net loss reflects General and administrative increase of 75% to $3M (expense) Research and development increase from $558K to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.22.

 FENCのテクニカル分析


 FENCのニュース

   Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update  2022/05/12 10:00:00 GlobeNewswire
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~
   U.S. FDA accepts Fennec Pharma''s New Drug Application (NDA) Resubmission for PEDMARK  2022/04/27 12:39:53 Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing of resubmitted New Drug Application (NDA) for PEDMARK TM (sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than 18 years of age with localized, non-metastatic, solid tumors. The … Full story available on Benzinga.com
   Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK  2022/04/27 10:00:00 Wallstreet:Online
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM
   Fennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapy  2022/03/24 10:33:47 Seeking Alpha
Fennec Pharmaceuticals (FENC) resubmitted an application to the U.S
   FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline  2022/03/24 09:45:00 Kwhen Finance
   U.S. FDA accepts Fennec Pharma''s New Drug Application (NDA) Resubmission for PEDMARK  2022/04/27 12:39:53 Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing of resubmitted New Drug Application (NDA) for PEDMARK TM (sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than 18 years of age with localized, non-metastatic, solid tumors. The … Full story available on Benzinga.com
   Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK  2022/04/27 10:00:00 Wallstreet:Online
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM
   Fennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapy  2022/03/24 10:33:47 Seeking Alpha
Fennec Pharmaceuticals (FENC) resubmitted an application to the U.S
   FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline  2022/03/24 09:45:00 Kwhen Finance
   ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FENC  2022/03/17 23:15:00 GlobeNewswire
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”), of the important April 11, 2022 lead plaintiff deadline .
   U.S. FDA accepts Fennec Pharma''s New Drug Application (NDA) Resubmission for PEDMARK  2022/04/27 12:39:53 Benzinga
Fennec Pharmaceuticals Inc. (NASDAQ: FENC ) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing of resubmitted New Drug Application (NDA) for PEDMARK TM (sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients one month to less than 18 years of age with localized, non-metastatic, solid tumors. The … Full story available on Benzinga.com
   Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK  2022/04/27 10:00:00 Wallstreet:Online
~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~ RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM
   Fennec refiles for FDA approval of Pedmark for preventing ototoxicity due to chemotherapy  2022/03/24 10:33:47 Seeking Alpha
Fennec Pharmaceuticals (FENC) resubmitted an application to the U.S
   FENC LAWSUIT ALERT: Levi & Korsinsky Notifies Fennec Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline  2022/03/24 09:45:00 Kwhen Finance
   ROSEN, A TOP RANKED LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FENC  2022/03/17 23:15:00 GlobeNewswire
NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the “Class Period”), of the important April 11, 2022 lead plaintiff deadline .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フェネック・ファ―マシュ―ティカルズ FENC Fennec Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)